Oragenics Inc. (OGEN) announced on Tuesday that it has successfully completed a key study for its innovative concussion drug, ONP-002. This study focused on evaluating the drug’s ability to reach the brain effectively through nasal delivery. The findings are promising, suggesting that ONP-002 can target specific areas within the nose connected to the brain, enhancing its potential to treat concussion-related symptoms.
The study utilized a nasal spray device to test ONP-002 in a cast metal anatomical model of the interior nose, a method approved by the FDA. The results demonstrated that the drug spreads efficiently within the nasal passages, enabling rapid absorption into the brain. This is particularly encouraging, as it opens the door for a quicker and more targeted approach to treating concussions.
Oragenics is now poised to move forward with human testing (Phase 2) in patients who present at the emergency room with concussions. The goal is to administer the first dose of ONP-002 within eight hours of the injury, aiming to mitigate the potential long-term consequences of concussions.
“The study results are promising, as they show the drug targets areas in the nose directly linked to the brain. This should increase the chances of the drug being effective in treating concussion and reduces the likelihood of it being swallowed, which is another encouraging sign,” said Michael Redmond, President of Oragenics.
The recent findings build upon previous research conducted by Oragenics. In August, the company completed a study indicating that ONP-002 does not cause cardiotoxicity, further bolstering its safety profile.
Concussions, which are mild traumatic brain injuries, are a significant public health concern, affecting an estimated 69 million individuals worldwide annually. While most people recover fully, up to 20% experience persistent symptoms, highlighting the need for effective treatments. Currently, no pharmaceutical treatment for concussions is available, making Oragenics’ progress particularly significant.
With the positive results from this recent study, Oragenics is taking a major step towards potentially revolutionizing the treatment of concussions. The company’s commitment to developing a safe and effective treatment option for these prevalent brain injuries could have a profound impact on the lives of countless individuals.
